on InDevR, Inc.
InDevR and Sino Biological Partner to Enhance Analytical Solutions for mRNA Vaccines and Cell & Gene Therapy
BOULDER, CO / ACCESSWIRE / June 5, 2024 / InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange, announced a new partnership. This collaboration seeks to develop multiplexed assays for various vaccine and therapy applications.
InDevR’s VaxArray Platform will now incorporate Sino Biological’s high-quality antibodies, antigens, and reagents. The biopharmaceutical industry benefits by accelerating the development of analytical tools crucial for mRNA, vaccine innovations, and cell and gene therapy advancements.
Dr. Kathy Rowlen, CEO of InDevR, emphasized the importance of this partnership in addressing the need for improved analytical tools. Dr. Rob Burgess, Chief Business Officer at Sino Biological, echoed this sentiment, highlighting the synergy between quality reagents and advanced analytical technology.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all InDevR, Inc. news